CORE--MOLECULAR BIOLOGY

分子生物学核心已经运行了九年 并为许多分子生物学提供了最先进的方法 生物技术以及重组蛋白表达， 洁净.分子生物学核心的主要目标是： 1.收集和保存合适的质粒载体和宿主， HIV/SIV和相关重组蛋白的表达。 2.为构建重组质粒和高通量测序提供服务。 HIV/SIV及其相关蛋白的水平表达。 3.为HIV/SIV及其相关蛋白的纯化提供服务。 4.建立带有HIV/SIV基因的质粒现场储存库， 以及重组HIV/SIV蛋白。 5.为构建具有传染性的HIV/SIV前病毒提供服务 在目的基因中含有确定突变的克隆。 6.培训人员协助质粒的各个阶段 重组蛋白的构建和表达/纯化 目的是促进技术转让。 分子生物学核心平均帮助了30多名CFAR成员 在上一个融资周期内。核心平均 在过去的三年半中，每年退款30，000美元，总计 本供资期间迄今为止的122 677美元。分子生物学 核心为UAB CFAR成员提供了关键试剂和专业知识 资助个人R 01赠款以及参与UAB 国家合作疫苗开发和国家合作药物 探索集团。因此，对该设施的支持对于 许多调查人员在不同领域的工作继续取得成功， 目前在UAB进行的HIV发病机制、疫苗和药物研究。

The Molecular Biology Core has been in operation for the past nine years and has provided state-of-the-art methodologies for numerous molecular biological techniques as well as recombinant protein expression and purification. The major goals of the Molecular Biology Core are: 1. To collect and maintain suitable plasmid vectors and host for expression of HIV/SIV and related recombinant proteins. 2. To provide a service for construction of recombinant plasmids and high level expression of HIV/SIV and related proteins. 3. To provide a service for purification of HIV/SIV and related proteins. 4. To establish an on-site repository for plasmids with HIV/SIV genes as well as recombinant HIV/SIV proteins. 5. To provide a service for construction of infectious HIV/SIV proviral clones containing defined mutations in genes of interest. 6. To train personnel to assist in the various phases of plasmid construction and expression/purification of recombinant proteins for the purpose of facilitating technology transfer. The Molecular Biology Core has assisted, on average, over 30 CFAR members per year during the last funding period. The Core has averaged over $30,000 per year in chargebacks over the last 3-1/2 years with a total of $122,677 to date for the current funding period. The Molecular Biology Core has provided critical reagents and expertise to UAB CFAR members which have funded individual R01 grants as well as participate in the UAB National Cooperative Vaccine Development, and National Cooperative Drug Discovery Group. Support of this facility is thus instrumental for the continued success of numerous investigators working in different areas of HIV pathogenesis, vaccine and drug studies currently conducted at UAB.